This study is a multi-center, observational study aiming to develop an early screening multi-model for detecting lung cancer signals through the integration of imaging (non-contrast CT) and blood testing (cfDNA methylation).
40-74 years old
Clinically and/or pathologically diagnosed cancer
No prior or undergoing any systemic or local antitumor therapy, including but not limited to surgical resection, radiochemotherapy, endocrinotherapy, targeted therapy, immunotherapy, interventional therapy, etc.
Able to provide a written informed consent and willing to comply with all part of the protocol procedures
Pregnancy or lactating women
Known prior or current diagnosis of other types of malignancies comorbidities
Severe acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.5 °C) within 14 days prior to screen
Recipients of organ transplant or prior bone marrow transplant or stem cell transplant
Shanghai Pulmonary Hospital, Shanghai, China
Lead sponsor
Shanghai Chest Hospital
Collaborator
Liaoning Cancer Hospital & Institute
Collaborator
The First Affiliated Hospital of Zhengzhou University
Collaborator
Yunnan Cancer Hospital
Collaborator
Shijiazhuang People's Hospital
Collaborator
The First Hospital of Jilin University
Collaborator